• BCN Peptides R&D on Atopic Dermatitis  

    September 4, 2019

    BCN Peptides included Atopic dermatitis in its research program. The project, enclosed in “Nuclis d’R+D empresarial” program from ACCIÒ, is cofinanced with the European Union FEDER funds.



  • CataloniaBio & HealthTech awards prize recognizing Dr. Antonio Parente´s professional career

    March 12, 2019

    The CataloniaBio & HealthTech night gathered more than 200 entrepreneurs, executives and investors from the biomedical field in the modernist enclosure of Sant Pau in Barcelona.

    The jury of the Employers Awards has granted a prize to Dr. Antonio Parente recognizing his professional trajectory. The prize was awarded by Health Counsellor, Alba Vergès.

    CataloniaBio & HealthTech recognized Dr. Antonio Parente, promoter of the Patronal in 2006, for his business trajectory. In 1987, Antonio Parente cofounded the Grupo Lipotec, which was sold years later in one of the biggest transactions of the, at that time, young Catalan biotech sector.

    Nowadays Dr. Antonio Parente is President and founder of GP Pharm and BCN Peptides.

    Dr. Antonio Parente highlighted that this award “wouldn´t have been possible without the business group´s professional human team”.

  • Nature publication First-in-Human Personalized Therapeutic Vaccine for Brain Cancer

    December 20, 2018

    BCN Peptides has been a key GAPVAC European Consortium member that has performed the first-in-human Clinical trial of a Personalized Therapeutic Vaccine to treat Glioblastoma. BCN Peptides role was the Manufacture of of the GMP Peptides Library used for the Vaccine production. We are proud to announce that the demonstration of the proof-of-concept for the Personalized approach has been published by Nature on date 19th December, 2018 (DOI 10.1038/s41586-018-0810-y). For more information you can download the GAPVAC Press release. BCN Peptides is completely committed with the growth of Personalized Medicine, as we consider this is a strategic therapy for the treatment of oncology patients in the near future. For this reason we are actively developing solutions for the challenges that Individualized Drug production represents for the Pharma Industry. GAPVAC press release_Nature